I am a healthcare professional

Notice

Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.

Cookies

We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site

Roche and Genentech at

SABCS 2024

December 10 - December 13

San Antonio, USA / Virtual (Hybrid)

sabcs.org

Medical Materials

Agenda

Coming soon

11:30 PM

Duration 29mins San Antonio, USA

First-line inavolisib/placebo + palbociclib + fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months of adjuvant endocrine therapy completion: long-term safety from INAVO120

Saura C, Turner NC, Jhaveri K, Im SA, Loibl S, Schmid P, Loi S, Juric D, Tryfonopoulos D, Bedard P, Yap YS, Villanueva V, Gokmen E, Bondarenko I, Wang X, Papazisis K, Thanopoulou E, Shankar N, Lim S, Jin Y, Song C, Stout T, Kalinsky K

Oncology | Breast Cancer

Duration 29mins San Antonio, USA

Real-world data on cyclin-dependent kinase 4/6 inhibitor switching in patients with first-line hormone receptor-positive, HER2-negative metastatic breast cancer

Chen L, Secrest M, Lopez-Valverde V, Perez-Moreno P, Kalinsky K, Zambelli A

Oncology | Breast Cancer

01:00 PM

Duration 30mins San Antonio, USA

ZN-1041, a potential best-in-class BBB Penetrable HER2 Inhibitor, has high antitumor activity in patients with Breast Cancer with CNS Metastases

Ma F, Li Y, Yao H, Wang J, Ouyang Q, Cheng J, Li X, Dinglin X-X, Jin G, Zhou H, Wang X, Teng Y, Wang Y, Dang Q, Yang J, Xiong H-H, Zhao W, Cai L, Fu T, Zhu D

Oncology | Breast Cancer

11:30 PM

Duration 29mins San Antonio, USA

pionERA Breast Cancer (BC): Phase III study of first-line (1L) giredestrant vs. fulvestrant, both combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), in patients (pts) with estrogen receptor-positive (ER+), HER2- locally advanced/metastatic BC (LA/mBC) with resistance to prior adjuvant endocrine therapy (ET)

Kalinsky K, Jeselsohn R, Bellet M, Fasching PA, Gomez-Abuin G, Jung KH, Lavalle S, Valverde VL, Lu YS, Schwab R, Turner NC, Breton VL, Zambelli A, Andre F

Oncology | Breast Cancer

Duration 29mins San Antonio, USA

Preliminary safety analysis of the inavolisib + fulvestrant + ribociclib/abemaciclib arms in MORPHEUS-pan BC: a phase Ib/II study evaluating the efficacy and safety of multiple treatment combinations in patients with metastatic or locally advanced breast cancer

Sonnenblick A, Loi S, Martin H, Oliveira M, Soong J, Young F, Cahuzac C, Shemesh C, Song C, Kallapur K, Schwab R, Gal-Yam E

Oncology | Breast Cancer

Duration 29mins San Antonio, USA

Real-world observational study of patients with endocrine-resistant, hormone receptor+, HER2– metastatic breast cancer in the first-line setting: Patient characteristics, PIK3CA mutation prevalence, treatments, and clinical outcomes

Dhillon P, Lambert P, Thanopoulou E, Kalinsky K

Oncology | Breast Cancer

06:30 PM

Duration 29mins San Antonio, USA

DEMETHER: A single-arm phase II trial to evaluate the efficacy and safety of subcutaneous fixed-dose combination of pertuzumab and trastuzumab maintenance after induction treatment with trastuzumab deruxtecan (T-DXd) for previously untreated human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC)

Cortés J, Garcia Mosquera JJ, Antonarelli G, Gennari A, Barrios C, Curigliano G, Rugo H, Gligorov J, Harbeck N, Tolaney S, Gradishar WJ, Schmid P, Gion M, Zhan RR, Szostak E, Gonzalez-Alonso P, Verbeni M, Parez-Garcia JM, Llombart-Cussac A

Oncology | Breast Cancer

11:30 PM

Duration 29mins San Antonio, USA

The global failure of mammography screening accessibility - a systematic literature review

Barrios C, Paluch-Shimon S, Muella E, Neeser K, Arnold M, Napalkov P, Azambuja E

Oncology | Breast Cancer